GlassScriptPhysician profile
Denice Gibson
$51,138.08
in general payments reported to CMS, 2019-2025
24 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $3,464 · 2023: $7,387 · 2024: $21K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $9,474 · Food and Beverage: $5,484 · Consulting Fee: $2,065 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,865.50 |
| Travel and Lodging | $9,473.82 |
| Food and Beverage | $5,484.36 |
| Consulting Fee | $2,065.00 |
| Education | $364.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,299.01 | 2022-2025 | |
| Janssen Biotech, INC. | $2,874.93 | 2023-2025 | Carvykti, Darzalex, Tecvayli |
| Jazz Pharmaceuticals INC. | $2,747.99 | 2022-2024 | Defitelio, Rylaze, Vyxeos |
| E.R. Squibb & Sons, L.L.C. | $2,048.23 | 2024 | Abecma |
| Kite Pharma, INC. | $843.08 | 2022-2025 | Yescarta |
| Celgene Corporation | $832.73 | 2021-2024 | Pomalyst, Reblozyl, Onureg |
| Sanofi-Aventis U.S. LLC | $353.45 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $265.65 | 2023-2025 | Livtencity, Iclusig, Cuvitru |
| Astellas Pharma US INC | $254.38 | 2023-2025 | Xospata |
| Seagen INC. | $199.69 | 2022-2023 | Adcetris |
| Glaxosmithkline, LLC. | $176.47 | 2022-2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $168.11 | 2022-2025 | Prevymis, Recarbrio, Dificid |
| Karyopharm Therapeutics INC. | $158.84 | 2025 | Xpovio |
| Amgen INC. | $130.95 | 2025 | Imdelltra (Amg757) |
| Genentech USA, INC. | $128.51 | 2023 | Lunsumio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $123.45 | 2024 | |
| Pfizer INC. | $116.47 | 2024 | |
| Syndax Pharmaceuticals, INC. | $112.73 | 2025 | Revuforj |
| Genzyme Corporation | $110.31 | 2022-2024 | |
| Legend Biotech USA INC. | $64.44 | 2025 | Carvykti |
| Novartis Pharmaceuticals Corporation | $59.57 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $25.46 | 2023 | Epkinly, Imbruvica |
| Stemline Therapeutics INC. | $23.90 | 2023 | Orserdu |
| Janssen Scientific Affairs, LLC | $19.73 | 2025 | Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denice Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.